Collectively, our current results demonstrated that SC attenuates bile acid metabolism disorder in NASH mice by activating FXR signaling in the liver and intestine, contributing to the amelioration of steatosis, inflammation, and fibrosis in NASH mice. Here, NR1H4 is linked to metabolic dysfunction-associated steatohepatitis.